

PROGRAM DESCRIPTION

It is estimated that 182,460 women and about 1,900 men will be diagnosed with breast cancer in the United States this year, making it the most frequently diagnosed non-skin cancer in women. Breast cancer ranks second as the cause of cancer deaths in women, with more than 40,930 deaths occurring this year as a result of the disease. Mortality secondary to breast cancer has decreased over the past 15 years secondary to improvements in screening and therapeutic interventions. The San Antonio Breast Cancer Symposium (SABCS) is an international forum for presentation of state-of-the-art information on the biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease. This program is designed to help physicians in their practice by bringing information from key presentations to local oncologists, gynecologists and radiologists who were unable to attend the national symposium. New options for the prevention, diagnosis and treatment of breast cancer and premalignant breast disease will be presented. In addition, we will discuss new strategies for optimizing existing treatments. Speakers will present information about the treatment of breast cancer, including local control, chemotherapy, hormonal therapy, prognosis and response predictors. Advances in breast cancer biologics and their impact on breast cancer management will be reviewed.

OBJECTIVES

After attending this program, participants should be able to:

1. review advances in the management of breast cancer and premalignant breast disease;
2. identify new strategies for optimizing existing treatments in these patients;
3. review new developments in breast cancer research and currently available clinical trials; and
4. integrate new findings into the management of patients with breast cancer and premalignant breast disease.

PROGRAM

6:00–6:30 pm	Registration
6:30 pm	Dinner
6:30–6:35 pm	Welcome and Overview <i>Lori J. Goldstein, M.D.</i>
6:35–6:55 pm	Risk and Prevention <i>Susan Domchek, M.D.</i>
6:55–7:15 pm	Local Control I <i>Richard J. Bleicher, M.D. F.A.C.S.</i>
	Local Control II <i>Gary M. Freedman, M.D.</i>
7:15–7:35 pm	Hormonal Therapy <i>Kevin R. Fox, M.D.</i>
7:35–7:55 pm	Chemotherapy <i>Crystal S. Denlinger, M.D.</i>
7:55–8:15 pm	Her 2 Targeting <i>Lori J. Goldstein, M.D.</i>
8:15–8:35 pm	Molecular Targeting and Therapeutics <i>Angela DeMichele, M.D., M.S.C.E.</i>

Questions will be answered immediately following each presentation.

TARGET AUDIENCE

This program is designed for medical, surgical and radiation oncologists, gynecologists and radiologists involved in the treatment of patients with breast cancer.

ACCREDITATION STATEMENT

The Fox Chase Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Fox Chase Cancer Center designates this educational activity for a maximum of **2.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

REGISTRATION AND PAYMENT

Please send Registration Form with check (**credit cards not accepted**) payable to **Fox Chase Cancer Center**, Attn: Kathy Truesdale, Office of CME, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

Registration Fee: \$25
(\$15 Fellows, Residents, Students)

Registration Deadline: January 2, 2009

Cancellations: Cancellations received prior to January 2, 2009, will be refunded in full.

INQUIRIES

For additional information, please contact the Office of Continuing Medical Education, Fox Chase Cancer Center
(Telephone: 215-728-5358; Fax: 215-214-8908; E-mail: kathy.truesdale@fcc.edu).

DIRECTIONS/PARKING

Directions/Location Map are available at www.hyatt.com.

Office of CME

333 Cottman Avenue
Philadelphia, PA 19111

**FOX CHASE
CANCER CENTER**

**HIGHLIGHTS OF THE 2008
SAN ANTONIO BREAST CANCER SYMPOSIUM**